Search research articles
Contact Us
Filters
Showing results (341-350 of 351) with videos related to
Page
of 36
Sort By:
Advances in Therapy
|
February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Hermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Advances in Therapy
|
December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
Clinical Lung Cancer
|
January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Advances in Therapy
|
November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Hermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Molecular Cancer Therapeutics
|
September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Dirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2023
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
Mary J van Helden, Seline A Zwarthoff, Roel J Arends, et al.
Nature
|
March 27, 2025
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Molecular Genetics and Metabolism
|
April 16, 2015
How strict is galactose restriction in adults with galactosaemia? International practice
S Adam, R Akroyd, S Bernabei, et al.
Molecular Genetics and Metabolism
|
April 12, 2015
Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach
A Aguiar, K Ahring, M F Almeida, et al.
Page
of 36
Search research articles
Search
Showing results (341-350 of 351) with videos related to
Sort By:
Page
of 36
Advances in Therapy
|
February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Hermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Advances in Therapy
|
December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
Clinical Lung Cancer
|
January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.
Advances in Therapy
|
November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Hermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Molecular Cancer Therapeutics
|
September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Dirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2023
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
Mary J van Helden, Seline A Zwarthoff, Roel J Arends, et al.
Nature
|
March 27, 2025
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Molecular Genetics and Metabolism
|
April 16, 2015
How strict is galactose restriction in adults with galactosaemia? International practice
S Adam, R Akroyd, S Bernabei, et al.
Molecular Genetics and Metabolism
|
April 12, 2015
Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach
A Aguiar, K Ahring, M F Almeida, et al.
Page
of 36